London, 24 September 2014: TechNavio, the independent tech-focused global research firm, has published a report on the Global Premature Ejaculation Market 2014-2018, which is expected to grow at a CAGR of 10.2 percent during the forecast period of 2013-2018.
Premature ejaculation is a sexual dysfunction in men wherein the semen is expelled with minimal penile or sexual stimulation. It is also known as rapid ejaculation, rapid climax, premature climax, and ejaculation praecox. It can be diagnosed using IELT, which is the average time taken by a man for ejaculation during vaginal penetration in sexual intercourse.
“The number of patients with premature ejaculation is increasing every day owing to an increase in an unhealthy lifestyle, and this is expected to boost the market in the near future,” says Faisal Ghaus, Vice President of TechNavio.
“Patients not responding to current treatments would still remain an untapped area of R&D for pharmaceutical companies to bring novel drugs into the market.”
Key Market Drivers
- Presence of Unmet Need
- Increase in Prevalence Rate
- Change in Lifestyle
Key Market Trends
- Increase in Awareness of Premature Ejaculation
- Increase in Strategic Alliances
Key Market Vendors
- Absorption Pharmaceuticals LLC
- Furiex Pharmaceuticals Inc.
- Innovus Pharmaceuticals Inc.
- Plethora Solutions Ltd.
To define the market circumstances in the next 3-4 years, TechNavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
